[Ip-health] GARD - WHO/DNDi initiative to develop new antibiotic treatments announces it has received seed funding
jarkinstall at dndi.org
Wed May 25 01:51:06 PDT 2016
Global Antibiotic Research and Development (GARD) Partnership Garners Key Financial Support for Launch
[24 May 2016 - Geneva] A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.
The mission of the Global Antibiotic Research and Development (GARD) Partnership is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. GARD is being incubated by the Drugs for Neglected Diseases initiative (DNDi) in collaboration with the World Health Organization (WHO).
2-pager on GARD including background, objectives, and WHO/DNDi respective roles here:
'We need more investment in research and development for new antibiotic treatments. Otherwise, we could lose the cornerstone of modern medicine, and infections and minor injuries which have been treatable may once again kill', said Dr Marie-Paule Kieny, WHO Assistant Director-General. 'But we also need to change the way we are using new antibiotics to slow down resistance building. GARD will endeavor to build in conservation aspects in the R&D process while making sure that any new products coming out of this initiative will be affordable for all.'
At the launch of the GARD Partnership on the occasion of the 69th World Health Assembly in Geneva, DNDi announced that it secured commitments for GARD from four governments - the Federal Ministry of Health of Germany, the Netherlands' Ministry of Health Welfare and Sports, the South African Medical Research Council, and the United Kingdom Department for International Development - as well as from the medical humanitarian organization Médecins Sans Frontières, totalling over EUR 2 million for the incubation phase of two years.
'GARD will apply a complementary approach to developing treatments to areas that have been inadequately addressed for decades by the current system for research and development', said Dr Bernard Pécoul, Executive Director, DNDi. 'GARD will focus on public health priorities, base its approach on partnership, and apply principles of openness and sharing of knowledge, as well as ensuring sustainable access to the treatments for the people who need them.'
GARD is currently exploring a number of possible short- to medium-term priority projects that would address gaps in the R&D pipeline and works on establishing a longer-term business plan. The objective of the incubation period is to have three to four projects financed and running by the end of 2017, with the aim of GARD becoming an independent entity at that time.
'GARD getting this support from donors from high- and middle-income countries alike is a sign of renewed political engagement to address this critical issue', said Dr Manica Balasegaram, newly appointed GARD Director. 'Today's pipelines are far too empty, so the global community has to take a range of different approaches that break from traditional market-driven "business as usual". We look forward to making an important contribution to this through GARD.'
James Arkinstall | Head of Communications and Advocacy|
Drugs for Neglected Diseases initiative
15 Chemin Louis-Dunant | 1202 Geneva | Switzerland
Tel: +41 22 9077 885 | Mob: +41 79 3929 823 jarkinstall at dndi.org<mailto:jarkinstall at dndi.org> | skype: dndi-james-arkinstall
Best Science for the Most Neglected | www.dndi.org<http://www.dndi.org/>
More information about the Ip-health